Segall Bryant & Hamill, LLC Tg Therapeutics, Inc. Transaction History
Segall Bryant & Hamill, LLC
- $7.1 Billion
- Q3 2025
A detailed history of Segall Bryant & Hamill, LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Segall Bryant & Hamill, LLC holds 77,833 shares of TGTX stock, worth $2.41 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
77,833
Previous 78,270
0.56%
Holding current value
$2.41 Million
Previous $2.82 Million
0.14%
% of portfolio
0.04%
Previous 0.04%
Shares
10 transactions
Others Institutions Holding TGTX
# of Institutions
395Shares Held
91.5MCall Options Held
2.1MPut Options Held
1.59M-
Vanguard Group Inc Valley Forge, PA15.5MShares$481 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$353 Million0.0% of portfolio
-
State Street Corp Boston, MA8.1MShares$251 Million0.01% of portfolio
-
Clearbridge Investments, LLC New York, NY4.64MShares$144 Million0.13% of portfolio
-
Geode Capital Management, LLC Boston, MA3.44MShares$107 Million0.01% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $4.5B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...